Matches in UGent Biblio for { ?s ?p Background and objectives: Xylosan polysulphate (XPS) is a polysaccharide with established connective tissue structure modifying properties in osteoarthritis (OA) cartilage. The objective of this study was to establish the clinical effects of XPS in patients (pts) with inflammatory hand OA. Methods: 50 pts suffering from inflammatory OA of their finger joints were included in a 24-week double-blind, randomized, placebo-controlled trial. Calcium XPS (CaXPS 20mg/kg per os) or placebo was given twice a week during two 6-weeks periods. Clinical observations were made at baseline, and every three weeks until week 24. Clinical variables studied were visual analogue scales (VAS) for global pain (primary outcome), morning stiffness, pain at night and dysfunction while conducting “heavy” and “light” daily activities. Other parameters included the grip-strength of and pain on palpation. Decrease of clinical scores was evaluated by mixed models analysis. Results: As expected, similar improvement in both placebo and CaXPS-treated groups was observed during the first period. However, from week 12 on, a significant difference between placebo and CaXPS-treated pts could be demonstrated for VAS global pain, morning stiffness, pain at night and dysfunction during light activities (Table). Conclusion: Although there is an important placebo response, this study demonstrated clinical efficacy of orally administered CaXPS, after prolonged treatment i.e. 24 weeks, and provided evidence of a positive response of the OA finger joints as a result of the structure modifying capacities of CaXPS.. }
Showing items 1 to 1 of
1
with 100 items per page.
- aggregation abstract "Background and objectives: Xylosan polysulphate (XPS) is a polysaccharide with established connective tissue structure modifying properties in osteoarthritis (OA) cartilage. The objective of this study was to establish the clinical effects of XPS in patients (pts) with inflammatory hand OA. Methods: 50 pts suffering from inflammatory OA of their finger joints were included in a 24-week double-blind, randomized, placebo-controlled trial. Calcium XPS (CaXPS 20mg/kg per os) or placebo was given twice a week during two 6-weeks periods. Clinical observations were made at baseline, and every three weeks until week 24. Clinical variables studied were visual analogue scales (VAS) for global pain (primary outcome), morning stiffness, pain at night and dysfunction while conducting “heavy” and “light” daily activities. Other parameters included the grip-strength of and pain on palpation. Decrease of clinical scores was evaluated by mixed models analysis. Results: As expected, similar improvement in both placebo and CaXPS-treated groups was observed during the first period. However, from week 12 on, a significant difference between placebo and CaXPS-treated pts could be demonstrated for VAS global pain, morning stiffness, pain at night and dysfunction during light activities (Table). Conclusion: Although there is an important placebo response, this study demonstrated clinical efficacy of orally administered CaXPS, after prolonged treatment i.e. 24 weeks, and provided evidence of a positive response of the OA finger joints as a result of the structure modifying capacities of CaXPS.".